Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) EBITDA (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed EBITDA for 6 consecutive years, with -$54.6 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 31.26% to -$54.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$274.8 million through Dec 2025, up 18.83% year-over-year, with the annual reading at -$274.8 million for FY2025, 18.83% up from the prior year.
  • EBITDA for Q4 2025 was -$54.6 million at Relay Therapeutics, up from -$73.5 million in the prior quarter.
  • The five-year high for EBITDA was -$42.2 million in Q1 2021, with the low at -$193.5 million in Q2 2021.
  • Average EBITDA over 5 years is -$80.5 million, with a median of -$77.8 million recorded in 2022.
  • The sharpest move saw EBITDA tumbled 603.88% in 2021, then skyrocketed 58.92% in 2022.
  • Over 5 years, EBITDA stood at -$68.6 million in 2021, then grew by 5.86% to -$64.5 million in 2022, then decreased by 24.44% to -$80.3 million in 2023, then increased by 1.0% to -$79.5 million in 2024, then skyrocketed by 31.26% to -$54.6 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$54.6 million, -$73.5 million, and -$70.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.